Related Experiment Video
Updated: Mar 19, 2026
06:21
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
1.4K
Pharmacogenetics of anthracyclines
Judit C Sági1, Nóra Kutszegi1, Andrea Kelemen1
1Department of Genetics, Cell- and Immunobiology, Semmelweis University, H-1089 Budapest, Nagyvárad tér 4, Hungary.
Pharmacogenomics
|June 9, 2016
Summary
Anthracyclines are effective cancer drugs but can harm the heart. Genetic variations influence these cardiac side effects, paving the way for personalized cancer treatment.
Area of Science:
- Oncology
- Pharmacogenetics
- Cardiology
Background:
- Anthracyclines are vital chemotherapy agents for various cancers in children and adults.
- Despite their efficacy, anthracyclines pose a significant risk of cardiotoxicity.
- Cardiac complications are observed in childhood cancer survivors treated with anthracyclines.
Purpose of the Study:
- To provide a comprehensive review of research on the pharmacogenetics of anthracyclines.
- To explore the influence of genetic variations on anthracycline-induced cardiotoxicity.
- To highlight the potential for personalized medicine in cancer therapy.
Main Methods:
- Literature review of scientific investigations on anthracycline pharmacogenetics.
- Analysis of studies examining genetic influences on cardiotoxicity.
- Synthesis of current research findings.
Main Results:
- Genetic variations in patients significantly impact the cardiotoxic effects of anthracyclines.
- Numerous studies have investigated the pharmacogenetics of these anticancer drugs.
- Genetic factors are crucial in understanding individual susceptibility to side effects.
Conclusions:
- Understanding genetic variants is key to mitigating anthracycline cardiotoxicity.
- Personalized dosing strategies based on genetic profiles can reduce adverse events.
- Pharmacogenetics offers a promising avenue for safer and more effective cancer treatment.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
65
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
98
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
98
01:29Pharmacogenetics and Pharmacogenomics: Overview
135
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
135
01:27Pharmacogenetics of Drug Metabolism: Overview
96
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
96
01:27Principles of Pharmacogenetics: Types of Genetic Variants
79
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
79
01:29Pharmacogenomics: Identification of New Drug Targets
75
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75